Alamar Biosciences, Inc.

ALMRUnited States

8 filed reports · 226 financial concepts · 2 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$74.2M

12 months to 2025-12-31 · to Dec 31, 2025

up +195% vs $25.1M

Filed report

Net income

-$29.8M

12 months to 2025-12-31 · to Dec 31, 2025

a year earlier: -$47.1M

Filed report

Operating income

-$31.3M

12 months to 2025-12-31 · to Dec 31, 2025

a year earlier: -$49.6M

Filed report

Latest quarter

Revenue

$33.5M

Q3 FY2026 · to Sep 30, 2026

up +68.5% vs $19.9M

10-Q

Net income

-$13.3M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$8M

10-Q

Operating income

-$15.1M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$7.89M

10-Q

Filed reports

8 reports · Mar 2026 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 operating metrics, 2 guidance figures, 73 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR3805Mar 2026 to Sep 2026
Current · 8-KSEC EDGAR26Jun 2026 to Sep 2026
Registration · S-1/ASEC EDGAR28Apr 2026
Registration · 424B4SEC EDGAR140Apr 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q310-Q2026-09-302026-11-04295Open
FY2026 Q38-K2026-09-302026-11-034Open
FY2026 Q210-Q2026-06-302026-08-11243Open
FY2026 Q28-K2026-06-302026-08-102Open
FY2026424B42026-04-172026-04-1740Open
FY2026S-1/A2026-04-162026-04-164Open
FY2026S-1/A2026-04-132026-04-134Open
FY2026 Q110-Q2026-03-312026-05-08267Open

Financial data

226 concepts · 859 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial205 concepts · 758 facts · Dec 2024 to Sep 2026

  • Revenue8 · Dec 2024 to Sep 2026
  • Additional Paid-in-Capital6 · Mar 2025 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value6 · Mar 2025 to Sep 2026
  • Allocated share based compensation expense6 · Mar 2025 to Sep 2026
  • Amortization of financing costs6 · Mar 2025 to Sep 2026
  • Amount recognized as contra research and development6 · Mar 2025 to Sep 2026
  • Antidilutive securities excluded from computation of earnings per share amount6 · Mar 2025 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations6 · Mar 2025 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect6 · Mar 2025 to Sep 2026
  • Comprehensive income net of tax6 · Mar 2025 to Sep 2026
  • Contract with customer liability revenue recognized6 · Mar 2025 to Sep 2026
  • Cost of revenue (US GAAP)6 · Mar 2025 to Sep 2026
  • Depreciation and amortization6 · Mar 2025 to Sep 2026
  • Earnings per share basic6 · Mar 2025 to Sep 2026
  • Earnings per share diluted6 · Mar 2025 to Sep 2026
  • Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations6 · Mar 2025 to Sep 2026
  • Fair value adjustment of warrants6 · Mar 2025 to Sep 2026
  • Fair value, assets, transfers into level 1, amount6 · Mar 2025 to Sep 2026
  • Fair value, assets, transfers into level 2, amount6 · Mar 2025 to Sep 2026
  • Fair value, assets, transfers out of level 1, amount6 · Mar 2025 to Sep 2026
  • Fair value, assets, transfers out of level 2, amount6 · Mar 2025 to Sep 2026
  • Fair value, liabilities, transfers into level 1, amount6 · Mar 2025 to Sep 2026
  • Fair value, liabilities, transfers into level 2, amount6 · Mar 2025 to Sep 2026
  • Fair value, liabilities, transfers out of level 1, amount6 · Mar 2025 to Sep 2026

Product2 concepts · 45 facts · Mar 2025 to Sep 2026

  • Revenue33 · Mar 2025 to Sep 2026
  • Cost of revenue (US GAAP)12 · Mar 2025 to Sep 2026

Geography1 concept · 26 facts · Mar 2025 to Sep 2026

  • Revenue26 · Mar 2025 to Sep 2026

Offering Terms14 concepts · 20 facts · Apr 2026

  • Securities Offered by Company3 · Apr 2026
  • Underwriters Option Securities3 · Apr 2026
  • Offering Price Range High2 · Apr 2026
  • Offering Price Range Low2 · Apr 2026
  • Dilution per Security to New Investors1 · Apr 2026
  • Lock-Up Period Days1 · Apr 2026
  • Net Tangible Book Value per Security After Offering1 · Apr 2026
  • Net Tangible Book Value per Security Before Offering1 · Apr 2026
  • Offering Gross Proceeds1 · Apr 2026
  • Offering Net Proceeds1 · Apr 2026
  • Offering Price per Security1 · Apr 2026
  • Shares Outstanding After Offering1 · Apr 2026
  • Underwriting Discount per Security1 · Apr 2026
  • Underwriting Discount Total1 · Apr 2026

Guidance2 concepts · 6 facts · Aug 2026 to Nov 2026

  • Revenue Guidance4 · Aug 2026 to Nov 2026
  • Revenue Growth Guidance2 · Nov 2026

KPI2 concepts · 4 facts · Mar 2026 to Sep 2026

  • Countries and Territories Covered2 · Mar 2026 to Sep 2026
  • Customer Count2 · Mar 2026 to Sep 2026

Segments

71 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service6 members · 45 facts

  • Product12 · Mar 2025 to Sep 2026
  • Service Other12 · Mar 2025 to Sep 2026
  • Consumables6 · Mar 2025 to Sep 2026
  • Instruments6 · Mar 2025 to Sep 2026
  • Service6 · Mar 2025 to Sep 2026
  • Product And Service Other3 · Mar 2025 to Sep 2025

Statement geographical5 members · 26 facts

  • Americas6 · Mar 2025 to Sep 2026
  • Asia Pacific6 · Mar 2025 to Sep 2026
  • EMEA6 · Mar 2025 to Sep 2026
  • US6 · Mar 2025 to Sep 2026
  • GB2 · Mar 2025 to Mar 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary13 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary60 claims from 2 reports · Apr 2026 to Sep 2026
  • Risk factors83 risks from 1 annual report

Earnings calls

2 calls · Aug 2026 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-03
  • FY2026 Q22026-08-10

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Alamar Biosciences, Inc. (ALMR) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

Alamar Biosciences, Inc. (ALMR): 12 months to 2025-12-31 revenue $74.2M · FactIQ